ERBB2 and breast cancer: Similarly, in 2023, another study aimed to assess the effectiveness of radiomic signatures derived from [18F]FDG PET/CT images in determining HER2 status in primary BC cases where immunohistochemistry (IHC) results for HER2 were inconclusive.